



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 17, 2004.

Patty Wilson
Patty Wilson
Date of Signature June 17, 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malouf e tal.

Group Art Unit: 1646

Serial No.: 10/726,216

Examiner: Unknown

Filed: December 2, 2003

Docket No.: 421/29/2/2

Confirmation No.: 4262

For: PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Forms PTO-1449 are attached hereto.

Copies of the cited documents are of record in the file history of U.S. Patent Application Serial No. 10/029,413 filed on December 20, 2001. The above-captioned application claims priority to U.S. Patent Application Serial No. 10/029,413 under 35

Serial No.: 10/726,216

U.S.C. § 120, and as per 37 C.F.R. § 1.98, no copies of these cited documents are believed to be required.


Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 06/17/2004

By: 
Arles A. Taylor, Jr.
Registration No. 39,395

AAT/ptw

Enclosures

Customer No: 25297



FORM PTO-100 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No. 421/29/2/2

Serial No.
10/726,216

List of Documents Cited by Applicant

Applicant(s): Malouf et al.

Filing Date: December 2, 2003

Group 1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
	1.	5,429,921	7/4/1995	Harpold et al.	435	4	
	2.	5,686,241	11/11/1997	Ellis et al.	435	56	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- | | |
|----|---|
| 3. | Hogan, et al. <i>Human dihydropyridine-sensitive L-type calcium channel alpha-1 subunit (CACNL1A3) mRNA</i> , Database accession no. L33798 XP002224388 (Abstract) (December 16, 1994). |
| 4. | Hogan et al., <i>The Structure of the Gene Encoding the Human Skeletal Muscle α_1 Subunit of the Dihydropyridine-Sensitive L-type Calcium Channel (CACNL1A3)</i> , <i>Genomics</i> 31:392-394 (1996). |
| 5. | Hogan et al., <i>Cloning of the human skeletal muscle alpha-1 subunit of dihydropyridine-sensitive L-type calcium channel</i> , <i>Genomics</i> 24, No. 3:608-609 (December 1 1994). |
| 6. | Chaudhari et al., <i>Mus musculus dihydropyridine sensitive skeletal muscle calcium channel mRNA</i> , Database accession no. L06234 XP002224389 (Abstract) (November 17, 1992). |
| 7. | Chaudhari, <i>A Single Nucleotide Deletion in the Skeletal Muscle-specific Calcium Channel Transcript of Muscular Dysgenesis (mdg) Mice</i> , <i>J. of Biological Chemistry</i> 267, No. 36:25636-25639 (1992). |

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 421/29/2/2	Serial No. 10/726,216
List of Documents Cited by Applicant		Applicant(s): Malouf et al.	
		Filing Date: December 2, 2003	Group 1646
	8.	Tang et al., <i>Molecular Localization Studies of the Dihydropyridine (DHP) Binding Site in the Cardiac L-type Voltage Dependent Ca²⁺ Channel (L-VDCC) α_1 Subunit Reveal Motif IV S3 to IV S6 as Essential</i> , XP000604115 (Abstract) (1993).	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY

Sheet 1 of 2

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 421/29/2/2		Serial No. 10/726,216	
List of Documents Cited by Applicant							
				Applicant(s): Malouf et al.			
				Filing Date: December 2, 2003		Group 1646	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
	1.	5,429,921	7/4/1995	Harpold et al.	435	4	
	2.	5,686,241	11/11/1997	Ellis et al.	435	56	
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Name of Patentee or Applicant		Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	3.	Hogan, et al. <i>Human dihydroxypyridine-sensitive L-type calcium channel alpha-1 subunit (CACNL1A3) mRNA</i> , Database accession no. L33798 XP002224388 (Abstract) (December 16, 1994).					
	4.	Hogan et al., <i>The Structure of the Gene Encoding the Human Skeletal Muscle α_1 Subunit of the Dihydropyridine-Sensitive L-type Calcium Channel (CACNLαA3), Genomics 31:392-394 (1996).</i>					
	5.	Hogan et al., <i>Cloning of the human skeletal muscle alpha-1 subunit of dihydroxypyridine-sensitive L-type calcium channel</i> , <u>Genomics</u> 24, No. 3:608-609 (December 1 1994).					
	6.	Chaudhari et al., <i>Mus musculus dihydropyridine sensitive skeletal muscle calcium channel mRNA</i> , Database accession no. L06234 XP002224389 (Abstract) (November 17, 1992).					
	7.	Chaudhari, <i>A Single Nucleotide Deletion in the Skeletal Muscle-specific Calcium Channel Transcript of Muscular Dysgenesis (mdg) Mice</i> , <u>J. of Biological Chemistry</u> 267, No. 36:25636-25639 (1992).					

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 421/29/2/2	Serial No. 10/726,216
List of Documents Cited by Applicant			
		Applicant(s): Malouf et al.	
		Filing Date: December 2, 2003	Group 1646
	8.	Tang et al., <i>Molecular Localization Studies of the Dihydropyridine (DHP) Binding Site in the Cardiac L-type Voltage Dependent Ca²⁺ Channel (L-VDCC) α_1 Subunit Reveal Motif IV S3 to IV S6 as Essential</i> , XP000604115 (Abstract) (1993).	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

176



JENKINS
WILSON
& TAYLOR

patent attorneys
June 17, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 17, 2004.

Patty Wilson
Patty Wilson
Date of Signature: June 17, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/726,216 for
PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL
NUCLEIC ACIDS AND POLYPEPTIDES AND
THERAPEUTIC AND SCREENING METHODS USING SAME
Our Ref. No. 421/29/2/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 pages) in duplicate; and
3. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.
Registration No. 39,395

AAT/ptw
Enclosures
Customer No: 25297

RICHARD E. JENKINS
JEFFREY L. WILSON
ARLES A. TAYLOR, JR.
GREGORY A. HUNT
E. ERIC MILLS
BENTLEY J. OLIVE
MICHAEL J. CROWLEY
CHRIS PERKINS, PH.D.
JAMES DALY IV, PH.D.
JEFFREY CHILDERS, PH.D.
OF COUNSEL
SOROJINI BISWAS

*LICENSED ONLY IN CA
**LICENSED ONLY IN KY